# A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

> **NCT03926143** · PHASE2 · TERMINATED · sponsor: **Bayer** · enrollment: 9 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** BAY94-9343 (Anetumab ravtansine)

## Key facts

- **NCT ID:** NCT03926143
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-03
- **Primary completion:** 2022-05-18
- **Final completion:** 2022-05-18
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Due to strategic company decisions, the development of anetumab ravtansine was stopped.
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03926143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03926143, "A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03926143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*